Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Tumor Immunotherapy
Immunocytochemistry and Immunohistochemistry
These...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.
CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.
Intracellular Oncoproteins Can Be Targeted by Mutation-Specific Dimeric IgA
Engineered dimeric IgA (dIgA) antibodies effectively target mutated oncodrivers within cancer cells, significantly inhibiting tumor growth. This novel immunotherapy approach shows promise for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cytoplasmic oncodrivers are key targets in cancer therapy.
- Dimeric IgA (dIgA) offers unique therapeutic potential due to its structure and effector functions.
- Engineering dIgA for specific intracellular targeting remains a challenge.
Purpose of the Study:
- To engineer dIgA antibodies capable of targeting mutated cytoplasmic oncodrivers.
- To evaluate the efficacy of engineered dIgA in abrogating tumor growth.
Main Methods:
- Development of dIgA constructs with specificity for intracellular oncodriver mutations.
- In vitro and in vivo models to assess dIgA delivery and anti-tumor activity.
- Analysis of tumor growth inhibition and potential mechanisms of action.
More Related Videos
08:12Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes
Published on: November 1, 2011
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
Main Results:
- Engineered dIgA successfully targeted mutated cytoplasmic oncodrivers.
- Significant abrogation of tumor growth was observed in treated models.
- Demonstrated the potential for intracellular antibody-based cancer therapy.
Conclusions:
- Engineered dIgA represents a promising strategy for targeting intracellular oncogenic drivers.
- This approach offers a novel therapeutic avenue for cancers driven by specific mutations.
- Further development could lead to new treatments for various malignancies.
